BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 26694325)

  • 21. Sulfated fucoidan FP08S2 inhibits lung cancer cell growth in vivo by disrupting angiogenesis via targeting VEGFR2/VEGF and blocking VEGFR2/Erk/VEGF signaling.
    Chen H; Cong Q; Du Z; Liao W; Zhang L; Yao Y; Ding K
    Cancer Lett; 2016 Nov; 382(1):44-52. PubMed ID: 27569654
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.
    Cao ZX; Zheng RL; Lin HJ; Luo SD; Zhou Y; Xu YZ; Zeng XX; Wang Z; Zhou LN; Mao YQ; Yang L; Wei YQ; Yu LT; Yang SY; Zhao YL
    Cell Physiol Biochem; 2011; 27(5):565-74. PubMed ID: 21691074
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cultivated Orostachys japonicus extract inhibits VEGF-induced angiogenesis via regulation of VEGFR2 signaling pathway in vitro and in vivo.
    Cho HD; Lee KW; Won YS; Kim JH; Seo KI
    J Ethnopharmacol; 2020 Jun; 256():112664. PubMed ID: 32045685
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo.
    Zhang S; Cao Z; Tian H; Shen G; Ma Y; Xie H; Liu Y; Zhao C; Deng S; Yang Y; Zheng R; Li W; Zhang N; Liu S; Wang W; Dai L; Shi S; Cheng L; Pan Y; Feng S; Zhao X; Deng H; Yang S; Wei Y
    Clin Cancer Res; 2011 Jul; 17(13):4439-50. PubMed ID: 21622720
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel inhibitor of c-Met and VEGF receptor tyrosine kinases with a broad spectrum of in vivo antitumor activities.
    Awazu Y; Nakamura K; Mizutani A; Kakoi Y; Iwata H; Yamasaki S; Miyamoto N; Imamura S; Miki H; Hori A
    Mol Cancer Ther; 2013 Jun; 12(6):913-24. PubMed ID: 23548264
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel angiogenesis inhibitory activity in cinnamon extract blocks VEGFR2 kinase and downstream signaling.
    Lu J; Zhang K; Nam S; Anderson RA; Jove R; Wen W
    Carcinogenesis; 2010 Mar; 31(3):481-8. PubMed ID: 19969552
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Isogambogenic acid inhibits tumour angiogenesis by suppressing Rho GTPases and vascular endothelial growth factor receptor 2 signalling pathway.
    Fan Y; Peng A; He S; Shao X; Nie C; Chen L
    J Chemother; 2013 Oct; 25(5):298-308. PubMed ID: 24070138
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination of bevacizumab and irradiation on uveal melanoma: an in vitro and in vivo preclinical study.
    Sudaka A; Susini A; Lo Nigro C; Fischel JL; Toussan N; Formento P; Tonissi F; Lattanzio L; Russi E; Etienne-Grimaldi MC; Merlano M; Milano G
    Invest New Drugs; 2013 Feb; 31(1):59-65. PubMed ID: 22714791
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Squalamine blocks tumor-associated angiogenesis and growth of human breast cancer cells with or without HER-2/neu overexpression.
    Márquez-Garbán DC; Gorrín-Rivas M; Chen HW; Sterling C; Elashoff D; Hamilton N; Pietras RJ
    Cancer Lett; 2019 May; 449():66-75. PubMed ID: 30771431
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anticancer imidazoacridinone C-1311 inhibits hypoxia-inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF) and angiogenesis.
    Paradziej-Łukowicz J; Skwarska A; Peszyńska-Sularz G; Brillowska-Dąbrowska A; Konopa J
    Cancer Biol Ther; 2011 Oct; 12(7):586-97. PubMed ID: 21775820
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A peptide mimicking the binding sites of VEGF-A and VEGF-B inhibits VEGFR-1/-2 driven angiogenesis, tumor growth and metastasis.
    Farzaneh Behelgardi M; Zahri S; Mashayekhi F; Mansouri K; Asghari SM
    Sci Rep; 2018 Dec; 8(1):17924. PubMed ID: 30560942
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A BMP7 Variant Inhibits Tumor Angiogenesis In Vitro and In Vivo through Direct Modulation of Endothelial Cell Biology.
    Tate CM; Mc Entire J; Pallini R; Vakana E; Wyss L; Blosser W; Ricci-Vitiani L; D'Alessandris QG; Morgante L; Giannetti S; Larocca LM; Todaro M; Benfante A; Colorito ML; Stassi G; De Maria R; Rowlinson S; Stancato L
    PLoS One; 2015; 10(4):e0125697. PubMed ID: 25919028
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PPemd26, an anthraquinone derivative, suppresses angiogenesis via inhibiting VEGFR2 signalling.
    Huang SW; Lien JC; Kuo SC; Huang TF
    Br J Pharmacol; 2014 Dec; 171(24):5728-42. PubMed ID: 25091695
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of vascular endothelial growth factor-induced angiogenesis by scopoletin through interrupting the autophosphorylation of VEGF receptor 2 and its downstream signaling pathways.
    Pan R; Dai Y; Gao XH; Lu D; Xia YF
    Vascul Pharmacol; 2011; 54(1-2):18-28. PubMed ID: 21078410
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tylophorine, a phenanthraindolizidine alkaloid isolated from Tylophora indica exerts antiangiogenic and antitumor activity by targeting vascular endothelial growth factor receptor 2-mediated angiogenesis.
    Saraswati S; Kanaujia PK; Kumar S; Kumar R; Alhaider AA
    Mol Cancer; 2013 Jul; 12():82. PubMed ID: 23895055
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of VEGF165/VEGFR2-dependent signaling by LECT2 suppresses hepatocellular carcinoma angiogenesis.
    Chen CK; Yu WH; Cheng TY; Chen MW; Su CY; Yang YC; Kuo TC; Lin MT; Huang YC; Hsiao M; Hua KT; Hung MC; Kuo ML
    Sci Rep; 2016 Aug; 6():31398. PubMed ID: 27507763
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
    Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM
    Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SKLB-M8 induces apoptosis through the AKT/mTOR signaling pathway in melanoma models and inhibits angiogenesis with decrease of ERK1/2 phosphorylation.
    Wang J; Yang Z; Wen J; Ma F; Wang F; Yu K; Tang M; Wu W; Dong Y; Cheng X; Nie C; Chen L
    J Pharmacol Sci; 2014; 126(3):198-207. PubMed ID: 25341684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Luteolin inhibits vascular endothelial growth factor-induced angiogenesis; inhibition of endothelial cell survival and proliferation by targeting phosphatidylinositol 3'-kinase activity.
    Bagli E; Stefaniotou M; Morbidelli L; Ziche M; Psillas K; Murphy C; Fotsis T
    Cancer Res; 2004 Nov; 64(21):7936-46. PubMed ID: 15520200
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Scopoletin, an active principle of tree tobacco (Nicotiana glauca) inhibits human tumor vascularization in xenograft models and modulates ERK1, VEGF-A, and FGF-2 in computer model.
    Tabana YM; Hassan LE; Ahamed MB; Dahham SS; Iqbal MA; Saeed MA; Khan MS; Sandai D; Majid AS; Oon CE; Majid AM
    Microvasc Res; 2016 Sep; 107():17-33. PubMed ID: 27133199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.